Ovid Therapeutics Inc (OVID) — Titan Protect Analysis

OVID

Ovid Therapeutics Inc

Healthcare · ·

$2.40

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$438M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.19

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-18.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.00

+108% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Ovid Therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the tr

https://www.ovidrx.com

Country: United States Employees: 23 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.605

Good returns relative to risk taken

Kelly Fraction

0.0046

Marginal edge — very small allocation suggested

Calmar Ratio

-0.112

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-10.3%

Historical annualised return based on price data

Max Drawdown

-92.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.18

Very low correlation to market moves

52W High

$3.11

23% below the year high

52W Low

$0.27

782% above the year low

Avg Volume

3,214,979

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.21

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

6.59

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-678.7%

Profit from core operations before interest and tax

Free Cash Flow

$-20,829,376

Negative — the business is spending more than it generates

Revenue (TTM)

$7M

Total revenue over the last 12 months

Net Income

$-24,072,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$7.00

Target Median

$5.00

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go